Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05988216 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

StatusUnknown
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 27, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Secondary endpoints: details revised at 1 of 2 entries
    • Eligibility criteria expanded, about 1 word
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2023 to Aug 14, 2023
    • Eligibility criteria expanded, about 6 words
    v3
  4. Eligibility criteria shortened, about 22 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.
Trial Details
NCT Number NCT05988216
Lead Sponsor Bioray Laboratories
Collaborators: First Affiliated Hospital of Zhejiang University
Conditions
(from sponsor)		 Systemic Lupus Erythematosus (SLE)
Related terms Lupus Erythematosus, Systemic
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov